All In Biotech

Drug Trial Radar · NCT05640245

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Dec 13, 2022

Primary completion

Sep 5, 2023

Study completion Jan 15, 2024

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Dec 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.

Conditions

  • Arthritis, Psoriatic

Interventions

  • SonelokimabDrug

    randomized treatment; parallel group

  • PlaceboDrug

    randomized treatment; parallel-group

  • AdalimumabDrug

    randomized treatment; parallel-group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12Time frame: At Week 12

Locations

42 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Rancho Mirage, California

  • Clinical Site

    Duncansville, Pennsylvania

  • Clinical Site

    Pleven, Bulgaria

  • Clinical Site

    Pleven, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Stara Zagora, Bulgaria

  • Clinical Site

    Varna, Bulgaria

  • Clinical Site

    Ostrava, Czechia

  • Clinical Site

    Tallinn, Estonia

  • Clinical Site

    Tartu, Estonia

  • Clinical Site

    Hamburg, Germany

  • Clinical Site

    Herne, Germany

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Székesfehérvár, Hungary

  • Clinical Site

    Szentes, Hungary

  • Clinical Site

    Veszprém, Hungary

  • Clinical Site

    Bialystok, Poland

  • Clinical Site

    Bialystok, Poland

  • Clinical Site

    Bialystok, Poland

  • Clinical Site

    Bydgoszcz, Poland

  • Clinical Site

    Bydgoszcz, Poland

  • Clinical Site

    Elblag, Poland

  • Clinical Site

    Gdynia, Poland

  • Clinical Site

    Krakow, Poland

  • Clinical Site

    Lodz, Poland

  • Clinical Site

    Nadarzyn, Poland

  • Clinical Site

    Nowa Sól, Poland

  • Clinical Site

    Olsztyn, Poland

  • Clinical Site

    Poznan, Poland

  • Clinical Site

    Sochaczew, Poland

  • Clinical Site

    Swidnica, Poland

  • Clinical Site

    Warsaw, Poland

  • Clinical SIte

    Wroclaw, Poland

  • Clinical Site

    Madrid, Spain

  • Clinical Site

    Sabadell, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.